Voir la source de 9 Worries To Ask Around PD0325901

boulardii [http://www.selleckchem.com/products/PD-0325901.html MAPK inhibitor] treatment. The primary outcome was the incidence of diarrhea defined as the percentage of patients developing a diarrhea. Diarrhea was defined as an increase in the frequency of bowel movements (>3/day) or decrease in stool consistency (Bristol stool scale 5 or 6). Secondary outcomes were: i) the onset of diarrhea, which was defined as the time between the inclusion of the patient and the onset of diarrhea; ii) the duration of diarrhea, which was defined as the number of days with diarrhea (the end of the diarrhea was defined as the moment when consistency (Bristol stool scale [http://en.wikipedia.org/wiki/GRB10 GRB10] 13C UBT. Table 1 Efficacy of Treatment and Severity of Diarrhea The sample size was calculated using the following formula N=Z2��[p��(1-P)]/E2=174 where N is the sample size, Z the confidence interval (=1.96), E the sampling error (=0.05) and P the incidence of AAD (=0.13). Data analysis was performed using SPSS 11.5 statistical software (Softonic; Softonic International S.A., http://en.softonic.com/s/spss-11.5-statistical-software-free-download). The onset time and duration of diarrhea were analyzed using two-tailed t-tests; p[http://www.selleckchem.com/products/epz-6438.html see more] while in the control group 26/92 (28.3%) patients had diarrhea (p the treatment group was 6.25��1.24 days, what was later than in the control group (4.05��1.11 days; p